I first ran into Onc-201 in October 2019. Families were already desperate to get a hold of it because the reports were so positive. Six years is too long to wait.
investor.jazzpharma.com/news-release...
investor.jazzpharma.com/news-release...
investor.jazzpharma.com
August 7, 2025 at 12:12 AM
I first ran into Onc-201 in October 2019. Families were already desperate to get a hold of it because the reports were so positive. Six years is too long to wait.
investor.jazzpharma.com/news-release...
investor.jazzpharma.com/news-release...
"To make determinations of efficacy, the agency will also begin use pre-existing, real-world safety data from other countries, with comparable regulatory standards, where the drug has already been studied in humans."
www.fda.gov/news-events/...
www.fda.gov/news-events/...
FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
FDA Plans to Phase Out Animal Testing Requirement
www.fda.gov
April 10, 2025 at 11:36 PM
"To make determinations of efficacy, the agency will also begin use pre-existing, real-world safety data from other countries, with comparable regulatory standards, where the drug has already been studied in humans."
www.fda.gov/news-events/...
www.fda.gov/news-events/...
Reposted
They are cutting cancer research. They are cutting cancer research. They can deny it all they want, but they are cutting cancer research. These are the cuts being made the DoD CDMRP cancer funding mechanism www.fightcancer.org/sites/defaul...
March 27, 2025 at 10:11 AM
They are cutting cancer research. They are cutting cancer research. They can deny it all they want, but they are cutting cancer research. These are the cuts being made the DoD CDMRP cancer funding mechanism www.fightcancer.org/sites/defaul...
Reposted
I will share more soon, but honored on behalf of a huge team and a very brave set of children and young adults to share in #NatureMedicine the first phase 1 trial of repeated intracranial B7-H3 CAR T cells and our very encouraging experience caring for patients with #DIPG.
🌟 NEW in #NatureMedicine: Repeat infusions of B7-H3 #CARTcells were safe in children with diffuse intrinsic pontine glioma (#DIPG). Median OS = 19.8 months vs historical OS = 11 months. 3 patients alive 40 months post-diagnosis! @nickvitanza.bsky.social #OncSky www.nature.com/articles/s41...
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial - Nature Medicine
In the final report of a phase 1 trial evaluating intracerebroventricular B7-H3-targeting CAR T cells in children and young adults with diffuse intrinsic pontine glioma, repeated intracranial infusion...
www.nature.com
January 7, 2025 at 3:34 PM
I will share more soon, but honored on behalf of a huge team and a very brave set of children and young adults to share in #NatureMedicine the first phase 1 trial of repeated intracranial B7-H3 CAR T cells and our very encouraging experience caring for patients with #DIPG.
DIPG statistics from Europe. Average patient age 7.5 y. Patients who by choice received no treatment had an OS of 3.0 months, those treated with radiation therapy alone had a OS of 10.4 m Those receiving RT combined with chemotherapy had OS of 11.7 m
academic.oup.com/noa/article/...
academic.oup.com/noa/article/...
Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG Registry
AbstractBackground. Our aim is to investigate the association of treatment with survival in patients with diffuse intrinsic pontine glioma (DIPG) by examin
academic.oup.com
December 3, 2024 at 12:34 AM
DIPG statistics from Europe. Average patient age 7.5 y. Patients who by choice received no treatment had an OS of 3.0 months, those treated with radiation therapy alone had a OS of 10.4 m Those receiving RT combined with chemotherapy had OS of 11.7 m
academic.oup.com/noa/article/...
academic.oup.com/noa/article/...